Acadian Asset Management LLC Mirati Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $10,730 - $17,505	386 Added 77.67%	883 $38,000
Q2 2023 Aug 07, 2023	BUY	$36.13 - $49.49 $17,956 - $24,596	497 New	497 $17,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $94,921 - $226,826	2,300 New	2,300 $102,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $318,135 - $720,680	8,124 Added 349.57%	10,448 $701,000
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $176,205 - $350,854	2,324 New	2,324 $189,000

Q2 2018 Jul 24, 2018	SELL	$26.05 - $52.4 $14,249 - $28,662	-547 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$17.2 - $34.95 $9,408 - $19,117	547 New	547 $17,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.